BRAFV600E mutation is associated with better prognoses in radioactive iodine refractory thyroid cancer patients treated with multi-kinase inhibitors: a retrospective analysis of registered clinical trials

Thyroid Research, Journal Year: 2025, Volume and Issue: 18(1)

Published: Feb. 9, 2025

The antiangiogenic multi-kinase inhibitors (MKIs) apatinib, donafenib, and anlotinib have demonstrated satisfactory efficacy in radioactive iodine refractory differentiated thyroid cancer (RAIR-DTC) their phase II/III trials. However, the potential impact factors on of these MKIs remain unclear. RAIR-DTC patients enrolled clinical trials our center were retrospectively reviewed. Kaplan–Meier method was used to examine relationship between clinicopathological variables progression-free survival (PFS) overall (OS), followed by a multivariate Cox analysis PFS. A total 71 progressive reviewed, which 26.7% treated anlotinib, 45.1% 28.2% donafenib. median follow-up time 44.1 months, PFS 21.1 estimated OS 47.7 months. showed no significant differences with or anlotinib. In univariate analyses, BRAFV600E mutation longer (HR 0.345, 95% CI 0.187–0.636, p < 0.001) 0.382, 0.166–0.878, = 0.019) compared wild-type BRAF. Patients follicular bone metastases had shorter PFS, worse Eastern Cooperative Oncology Group performance status, metastases, larger tumor burden OS. analysis, only independent predictor 0.296, 0.138–0.638, 0.002). response rate disease control didn't differ status. Subgroup papillary stratified status that associated all subgroups (hazard ratio 1). achieved better prognoses BRAF, indicating genetic background may play role predicting therapies. This retrospective cohort included from apatinib (NCT02731352, NCT03048877), donafenib (NCT02870569, NCT03602495), (NCT05007093).

Language: Английский

Prognostic Factors for Cancer-Specific Survival and Disease-Free Interval in 130 Patients with Follicular Thyroid Carcinoma: Single Institution Experience

Diagnostics, Journal Year: 2024, Volume and Issue: 14(24), P. 2817 - 2817

Published: Dec. 14, 2024

Background: Follicular thyroid carcinoma (FTC) is categorized into three groups: minimally invasive FTC (MIFTC), encapsulated angioinvasive (EAIFTC), and widely (WIFTC). the second most common type of tumor, though it remains relatively rare in general population. This study aimed to examine prognosis prognostic factors patients with follicular carcinoma. Methods: Data were obtained from a tertiary referral center for 130 patients, covering period 1995 2020. Clinical data included demographic characteristics, tumor features, surgery, recurrence, vital status. Descriptive statistical methods, Kaplan–Meier survival curves, Cox proportional hazard regression used analysis identify independent predictors. Results: Distant metastases occurred 12 during follow-up period. The 5-year, 10-year, 15-year, 20-year cancer-specific (CSS) rates 98.1%, 92.3%, 83.5%, 79.8%, respectively. Independent unfavorable CSS (hazard ratio [HR] 3.63, 95% CI 1.29–10.18), multifocality (HR 6.7, 1.37–32.72), presence distant 2.29, 1.08–4.84). When disease-free interval (DFI) was considered, 85.3%, 82.0%, 76.6%, DFI 2.53, 1.02–6.28) 7.69, 1.07–55.17). Conclusions: 10-year rate favorable. Factors associated poorer include metastases, WIFTC, multifocality. linked disease recurrence are WIFTC

Language: Английский

Prognosis and influencing factors of follicular thyroid cancer

Cancer Medicine, Journal Year: 2023, Volume and Issue: 13(1)

Published: Dec. 16, 2023

Follicular thyroid cancer (FTC) is prone to distant metastasis, and patients with metastasis often have poor prognosis. In this study, the impact of other relevant factors on prognosis follicular carcinoma was examined.

Language: Английский